Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up
- 16 January 2009
- journal article
- Published by Springer Nature in Eye
- Vol. 23 (11), 2042-2045
- https://doi.org/10.1038/eye.2008.404
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Intravitreal Bevacizumab Treatment for Choroidal Neovascularization in Pathologic Myopia: 12-month ResultsAmerican Journal of Ophthalmology, 2008
- Intravitreal Bevacizumab for Choroidal Neovascularization Attributable to Pathological Myopia: One-Year ResultsAmerican Journal of Ophthalmology, 2008
- Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neovascularization: one‐ and two‐year follow upClinical & Experimental Ophthalmology, 2008
- Intravitreal Bevacizumab (Avastin) for Myopic Choroidal NeovascularizationOphthalmology, 2007
- Intravitreal Bevacizumab for Choroidal Neovascularization Caused by AMD (IBeNA Study): Results of a Phase 1 Dose-Escalation StudyInvestigative Opthalmology & Visual Science, 2006
- Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopiaOphthalmology, 2003
- Long-term visual prognosis of choroidal neovascularization in high myopia: A comparison between age groupsOphthalmology, 2002
- Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularizationOphthalmology, 1999
- Etiology of Choroidal Neovascularization in Young PatientsOphthalmology, 1996